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Atherectomy’s Ability to Leave No Trace or Need for More
DEFINITIVE Data?*Andrew J.P. Klein, MDI n the 1960s, the conservation principle of“Leave No Trace” emerged as a way to preservethe environment for future generations. At the
turn of this century in the vascular realm, there
was the development of nonstent strategies for the
endovascular treatment of infrainguinal peripheral
arterial disease to similarly preserve the native
vessel. This approach provides numerous advan-
tages, including the preservation of future potential
surgical targets and the natural conformability of
the vessel while avoiding the placement of a reste-
nosis nidus. The challenge that plagues nonstent
technologies, such as directional atherectomy, isSEE PAGE 923the dearth of randomized clinical trials and compar-
ative effectiveness data to support their use. Indeed,
many have noted the nonuniformity of the current
endovascular literature (1), citing the relatively small
patient numbers studied, the lack of core laboratory
adjudication of residual stenosis and/or patency,
and the limited long-term clinical follow-up. In this
issue of JACC: Cardiovascular Interventions, the
DEFINITIVE LE (Determination of EFfectiveness of
the SilverHawk PerIpheral Plaque ExcisioN System
(SIlverHawk Device) for the Treatment of Infraingui-
nal VEssels / Lower Extremities) Investigators (2)
present the 1-year results of a large, multicenter*Editorials published in the JACC: Cardiovascular Interventions reﬂect the
views of the authors and do not necessarily represent the views of JACC:
Cardiovascular Interventions or the American College of Cardiology.
From the St. Louis VA Healthcare System, Department of Medicine, Di-
vision of Cardiology, St. Louis, Missouri; and the Department of Medi-
cine, Division of Cardiology, Saint Louis University School of Medicine,
St. Louis, Missouri. Dr. Klein has reported that he has no relationships
relevant to the contents of this paper to disclose.study of directional atherectomy and argue that
indeed we can treat infrainguinal disease while
“leaving no trace.”
The need for an effective yet minimally invasive
treatment of infrainguinal disease is clear. With a
current worldwide estimate of 202 million people
living with peripheral arterial disease (3) and the
obesity epidemic driving a rise in diabetes, the in-
vestigators appropriately highlight the predicted
552 million people who will be living with peripheral
arterial disease by 2030 (4,5). Of this group, a large
number will have symptoms refractory to medical
and/or exercise therapy and that will require
revascularization. For these patients, the vascular
specialist must determine which revascularization
strategy confers the lowest risk to the patient while
ensuring the highest long-term patency. A barrier
to this goal is the diffuse, calciﬁc nature of infrain-
guinal atherosclerosis along with its high propensity
for progression to occlusive disease. These vessels
are additionally subjected to well-documented com-
plex 3-dimensional biophysical forces (6) that have
been shown to limit the success of endovascular
stenting (7). In response, some operators choose to
use angioplasty alone as the primary strategy for
infrainguinal revascularization, yet this technique is
associated with high restenosis rates, particularly in
the treatment of long lesions (8). Many operators
choose to use stents based on data showing an
enhanced patency over angioplasty in the femo-
ropopliteal segment (9), the relative ease of the
procedure, and the high procedural success rate.
Stenting, however, leaves a permanent implant that
can limit future therapies, can alter the conformity of
the vessel, and carries the risk of stent fracture and its
associated elevated restenosis rates (7). This reste-
nosis is often diffuse (10) and represents a major
limitation of stenting as it is both challenging to treat
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935as well as to preclude from reoccurring. All of these
factors have contributed to interest in debulking
strategies to treat obstructive infrainguinal disease.
Directional atherectomy is 1 such strategy that phys-
ically removes the obstructing arterial atheroma,
potentially obviating the need for a permanent
implant.
Data for the use of directional atherectomy is from
registries or is limited to single centers and subject to
selection bias. These studies were plagued further by
the errors associated with interobserver variability
when reporting percentage of residual stenosis or
restenosis. As such, patency rates have widely
varied across these studies (11) depending on patient
and/or lesion characteristics and study methodology.
DEFINITIVE-LE was designed to address some of
these limitations by being a large prospective registry
with core laboratory adjudication. The study was also
designed to answer whether atherectomy is as effec-
tive in diabetic as well as nondiabetic claudicants
given the decreased efﬁcacy of endovascular thera-
pies noted previously in this group. The primary
endpoint was divided by presentation status, that is,
primary patency for claudicants versus freedom from
unplanned amputation in critical limb ischemia (CLI)
patients at 12 months.
Several aspects of the study group should be
noted. First, the patient population consisted of
45% women, and as women typically have smaller
vessels than men, restenosis/reocclusion can occur
more frequently in this patient subset. Although
DEFINITIVE LE permitted inclusions up to 200 mm,
the majority of the lesions were evenly divided
among <50, 50 to 100, and >100 mm with a mean
lesion length of 75 mm, which is comparable to
contemporary stent trials. Operators familiar with
directional atherectomy also will note a reported
average procedural time of just over 1 h (71 min)
with a mean ﬂuoroscopy time of 20 min despite a
mean stenosis of 74% and an average lesion length
of 73 mm, which either reﬂects a highly experi-
enced group of operators or suggests more focal
disease.
Notably, in this large registry, there was a 5.3%
arterial perforation rate that is alarmingly high and
likely is a byproduct of the small vessels included
(mean reference lumen diameter 4.2  1.2 mm), use of
atherectomy in the subintimal space, and atherec-
tomy of infrapopliteal vessels, which are smaller and
require a less aggressive technique. In contrast, there
is a relatively low rate of distal embolization reported
(mean 3.8%, n ¼ 30), despite only a 20% use of
embolic protection. This highlights the experience
of the operators and less calciﬁc disease, asembolization is both lesion- and technique-driven.
Although the investigators report that there was no
difference in distal embolization with or without a
ﬁlter, the event rate is too small to have detected a
difference, and operators should consider placement
of embolic protection for these procedures to truly
“leave no trace.”
Finally, the primary 1-year patency of treated
vessels in claudicants (Duplex ultrasound peak sys-
tolic velocity ratio <2.4) was 78% overall, which is
comparable to contemporary stent trials. Surpris-
ingly, given the small caliber of these vessels, infra-
popliteal vessels remained 90% patent at 1 year.
Additionally, noninferiority of this revascularization
strategy in diabetic versus nondiabetic claudicants
was demonstrated, which is interesting and demands
future study. Limb preservation was achieved in
95% of cases in the CLI group, which exceeds most
surgical studies (12,13).
Although all nonstent technologies lack large ran-
domized data to support their use, proponents of
directional atherectomy underscore the ability of this
approach to preclude stenting; in this large registry,
the overall stent bailout rate was 3.2%. In Table 8
of their paper, McKinsey et al. (2) appropriately
compare their results with those of contemporary
nitinol stent trials. They found that for superﬁcial
femoral artery lesions <100 mm, directional atherec-
tomy achieves similar patency rates at 1 year without
the need to place a permanent intravascular device.
Readers will also note the infrapopliteal lesion sub-
group results where the patency rates (mean lesion
length 55 mm in claudicants and 60 mm in CLI) sur-
passed that of the ACHILLES study (Comparing An-
gioplasty and DES in the Treatment of Subjects With
Ischemic Infrapopliteal Arterial Disease Study) (14),
wherein drug-eluting stents were placed (mean lesion
length 27 mm).
The major weakness of DEFINITIVE LE, as in pre-
vious studies of directional atherectomy, lies in its
lack of a randomization to a comparative arm. At the
time of the study’s creation, there were no U.S. Food
and Drug Administration—approved nitinol stents for
the femoropopliteal segment, precluding a random-
ized clinical trial, and it was stated that comparison
to balloon angioplasty would have been inadequate
given the poor patency associated with balloon alone.
Indeed, it is disappointing that to date there have been
no large randomized head-to-head trials of atherec-
tomy (any device) versus stenting in the periphery.
The strengths of this registry are its large size, use
of core laboratory adjudication, and diversiﬁed pa-
tient population. DEFINITIVE LE demonstrates that it
is possible to effectively treat atherosclerotic disease
Klein J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 7 , N O . 8 , 2 0 1 4
Leave No Trace vs. More Deﬁnitive Data Needed A U G U S T 2 0 1 4 : 9 3 4 – 6
936of the infrainguinal vessels with directional atherec-
tomy. The investigators cite the exciting prospect of
combination therapy of atherectomy with a drug-
coated balloon and cite a small single-center study
(n ¼ 30) of heavily-calciﬁed femoropopliteal vessels
treated with this approach that reported a 1-year
primary patency rate of 90% (15). Perhaps direc-
tional atherectomy may not only preserve the vessel,
but also prepare the vessel for adjunctive more
deﬁnitive therapies such as drug-coated balloons.
Overall, the DEFINITIVE LE trial suggests that direc-
tional atherectomy for the treatment of claudicationand CLI is a promising “leave no trace” endovascular
strategy, but we are still left with the need for ran-
domized comparative data examining directional
atherectomy versus stent therapy, that is, more
deﬁnitive data, prior to fully embracing this technol-
ogy in the periphery.
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